Drugs that contain Glycopyrronium Tosylate

1. List of Qbrexza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10548875 JOURNEY Glycopyrrolate salts
Feb, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10052267 JOURNEY Topical glycopyrrolate formulations
Oct, 2028

(5 years from now)

US8618160 JOURNEY Topical glycopyrrolate formulations
Dec, 2029

(6 years from now)

US9744105 JOURNEY Topical glycopyrrolate formulations
Jul, 2030

(7 years from now)

US10004717 JOURNEY Glycopyrrolate salts
Feb, 2033

(10 years from now)

US10543192 JOURNEY Glycopyrrolate salts
Feb, 2033

(10 years from now)

US8859610 JOURNEY Crystalline glycopyrrolate tosylate
Feb, 2033

(10 years from now)

US9259414 JOURNEY Glycopyrrolate salts
Feb, 2033

(10 years from now)

Market Authorisation Date: 28 June, 2018

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH;TOPICAL

How can I launch a generic of QBREXZA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in